BiotechTube
Atia Vision

Atia Vision

Menlo Park, United States· Est.
atiavision.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $45M

Overview

Atia Vision, founded in 2016 and based in Campbell, California, is a private ophthalmic device innovator focused on the large unmet need in cataract surgery. Its lead product, the OmniVu™ IOL, is a dual-optic, fluid-filled lens designed to restore natural accommodation, potentially offering superior near-to-distance vision without the side effects of current premium lenses. The company achieved a critical milestone in May 2025 with FDA IDE approval to begin a U.S. feasibility study, supported by a $42M Series E financing round closed in 2022.

Ophthalmology

Technology Platform

Proprietary modular, dual-optic intraocular lens (IOL) system featuring a shape-changing, fluid-filled base and a fixed-power front optic. Designed to harness the eye's natural accommodative mechanism to restore dynamic focus from near to distance.

Funding History

2
Total raised:$45M
Series B$30M
Series A$15M

Opportunities

The aging global population drives a large and growing market for cataract surgery, with increasing patient demand for premium lenses that provide full vision range without glasses.
Significant unmet need exists for an accommodating IOL that does not cause halos, glare, or other visual disturbances common with current technologies, positioning OmniVu™ for potential high adoption if clinical data is positive.

Risk Factors

The novel, fluid-based dual-optic design faces clinical and regulatory risks, including the need to prove long-term safety and efficacy to the FDA.
As a pre-revenue startup, Atia must also overcome commercialization challenges in a market dominated by large, entrenched competitors with extensive surgeon relationships and reimbursement infrastructures.

Competitive Landscape

Atia Vision competes in the premium intraocular lens (IOL) market against giants like Alcon (AcrySof® IQ PanOptix®, Vivity®), Johnson & Johnson Vision (TECNIS® Symfony®, Synergy®), and Bausch + Lomb (Crystalens®). Its key differentiation is the aim to provide true, dynamic accommodation via a shape-changing mechanism, unlike current multifocal (which split light) or extended depth-of-focus (EDOF) lenses.

More companies in Digital Health & Biotech SaaS →More companies in United States →